Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)

DiscussionThe causal inference and pathophysiology of LVH regression by FGF23 reduction using calcimimetic treatment has not yet been shown. This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis. It might be speculated that successful treatment of cardiac morphology will also reduce the risk of cardiac death in this population.Trial registrationEuropean Clinical Trials Database, EudraCT number 2017-000222-35; ClinicalTrials.gov,NCT03182699. Registered on
Source: Trials - Category: Research Source Type: clinical trials